SUBSCRIBE
SUBSCRIBE
Ana Mulero

Ana Mulero

Freelance writer

Ana Mulero is a freelance writer based in Puerto Rico and Florida. She can be reached at anacmulero@outlook.com, on LinkedIn and on X @anitamulero.

Policy
Makena Saga Concludes as FDA Withdraws Approval for Only Preterm Birth Drug on Market
After 12 years on the market, the FDA announced it has withdrawn its previous approval for the only drug on the market to prevent preterm birth, Covis Pharma’s Makena.
April 7, 2023
 · 
3 min read
 · 
Ana Mulero
Pictured: Cancer patient in bed looking out window
Drug Development
Oncternal Therapeutics Cuts Two Programs Amidst Changing BTK Landscape
The money saved on canceling the existing studies is intended to fund the advancement of two other oncology pipeline assets.
April 4, 2023
 · 
2 min read
 · 
Ana Mulero
Leon Neal/Getty Images
Drug Development
GSK Expands Infectious Disease Pipeline With $593M SCYNEXIS Deal
GSK will help commercialize Brexafemme (ibrexafungerp), currently approved to treat vaginal yeast infections and vulvovaginal candidiasis (VVC).
March 30, 2023
 · 
2 min read
 · 
Ana Mulero
Business
Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1
Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.
March 29, 2023
 · 
3 min read
 · 
Ana Mulero
Drug Development
UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea
UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.
March 27, 2023
 · 
1 min read
 · 
Ana Mulero
A man sits with head in hands/Courtesy of Shutters
Drug Development
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder.
March 24, 2023
 · 
2 min read
 · 
Ana Mulero
Courtesy of joreks/Getty Images
Novo Nordisk Inks Deal with Dewpoint Therapeutics to Boost Diabetes Portfolio
Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter’s biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.
March 23, 2023
 · 
1 min read
 · 
Ana Mulero
Courtesy of Tada Images/Getty Images
Drug Development
Gilead’s Yescarta Bests Long-Time Standard of Care in R/R LBCL Overall Survival
Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead’s Kite Pharma.
March 22, 2023
 · 
1 min read
 · 
Ana Mulero
Pictured: Woman stepping onto scale/Courtesy Getty
Drug Development
Altimmune Obesity Drug Well-Positioned Despite Safety Data
Mayank Mamtani, managing director and group head of healthcare research at B. Riley Securities, told BioSpace he believes Altimmune’s pemvidutide still shows promise despite safety concerns.
March 22, 2023
 · 
2 min read
 · 
Ana Mulero
Drug Development
Mereo Forges Ahead with PRO Trial Design for Lung Disease Program
Following recent meetings with the FDA and European Medicines Agency, Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.
March 21, 2023
 · 
2 min read
 · 
Ana Mulero
Image courtesy of Getty Images
Drug Development
Takeda’s $4B Plaque Psoriasis Candidate Clears Mid-Stage Study
Takeda will advance its experimental drug for plaque psoriasis, TAK-279, to Phase III later this year after the TYK2 inhibitor met its primary and secondary endpoints in a Phase IIb study.
March 20, 2023
 · 
1 min read
 · 
Ana Mulero
Load More